Devopharma ApS: Financial statements 2021
CVR: 38968254
Source: annual report 2021, Danish Business Authority
01/01/2021 – 31/12/2021
Devopharma ApS (CVR 38968254) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity in the 2021 report amounted to DKK 37,500. The solvency ratio was 37.5%.
- Gross Profit
- DKK -3,125
- Profit/Loss
- DKK -3,125
- Equity
- DKK 37,500
- Total Assets
- DKK 100,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2021 | - | -3 t. | -3 t. | 38 t. | 0 |
| 2020 | - | -3 t. | -3 t. | 41 t. | 0 |
| 2019 | - | -3 t. | -3 t. | 44 t. | 0 |
Find more companies like Devopharma ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorEvents in 2021
Devopharma ApS has published its annual report for 2020. Gross profit came to DKK -3,125, and the net result was DKK -3,125.
As of June 30, 2021, MBA STATSAUTORISERET REVISIONSANPARTSSELSKAB has stepped down as auditor of Devopharma ApS.
About Devopharma ApS
Devopharma ApS is a Danish company of the type Anpartsselskab based in Charlottenlund, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Henrik Nakskov and Søren Luplau-Pagh. The company's owners include JARCO HOLDING ApS, HN HOLDING 2010 ApS and Friendly Holding ApS. In 2025, the company reported a gross profit of DKK -3,125 and a net result of DKK -3,125 compared with DKK -3,125 the year before. Equity in the 2025 report amounted to DKK 25,000.